Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NP 001

Next Previous
Drug Profile

NP 001

Alternative Names: NP 001 - Neuvivo; NP-001

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer Neuraltus Pharmaceuticals; Neuvivo
  • Class Antidementias; Antiparkinsonians; Neuropsychotherapeutics; Small molecules; Vascular disorder therapies
  • Mechanism of Action Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Amyotrophic lateral sclerosis
  • Phase I Frontotemporal dementia; Huntington's disease; Multiple sclerosis; Muscular dystrophies
  • No development reported Alzheimer's disease; Immunological disorders; Parkinson's disease; Vascular dementia
  • Discontinued Ataxia telangiectasia

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Immunological-disorders in USA
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Parkinson's-disease in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top